Complement C3 is a novel modulator of the anti-factor VIII immune response

• Published in: Haematologica (Roma) Vol. 103; no. 2; pp. 351 - 360
• Main Authors: Rayes, Julie, Ing, Mathieu, Delignat, Sandrine, Peyron, Ivan, Gilardin, Laurent, Vogel, Carl-Wilhelm, Fritzinger, David C., Frémeaux-Bacchi, Véronique, Kaveri, Srinivas V., Roumenina, Lubka T., Lacroix-Desmazes, Sébastien
• Format: Journal Article
• Language: English
• Published: Italy Ferrata Storti Foundation 01.02.2018
• Subjects: Animals; Antibodies, Neutralizing - immunology; Antigen Presentation - immunology; Complement Activation; Complement C3 - pharmacology; Dendritic Cells - physiology; Endocytosis - drug effects; Factor VIII - immunology; Hematology; Human health and pathology; Humans; Immunity - drug effects; Life Sciences; Mice
• ISSN: 0390-6078; 1592-8721; 1592-8721
• DOI: 10.3324/haematol.2017.165720

Development of neutralizing antibodies against therapeutic Factor VIII (FVIII) is the most serious complication of the treatment of hemophilia A. There is growing evidence to show the multifactorial origin of the anti-FVIII immune response, combining both genetic and environmental factors. While a role for the complement system on innate as well as adaptive immunity has been documented, the implication of complement activation on the onset of the anti-FVIII immune response is unknown. Here, using assays for FVIII endocytosis by human monocyte-derived dendritic cells and presentation to T cells, as well as complement depletion in FVIII-deficient mice, we show a novel role for complement C3 in enhancing the immune response against therapeutic FVIII. , complement C3 and its cleavage product C3b enhanced FVIII endocytosis by dendritic cells and presentation to a FVIII-specific CD4 T-cell hybridoma. The C1 domain of FVIII had previously been shown to play an important role in FVIII endocytosis, and alanine substitutions of the K2092, F2093 and R2090 C1 residues drastically reduce FVIII uptake Interestingly, complement activation rescued the endocytosis of the FVIII C1 domain triple mutant. In a mouse model of severe hemophilia A, transient complement C3 depletion by humanized cobra venom factor, which does not generate anaphylatoxin C5a, significantly reduced the primary anti-FVIII immune response, but did not affect anti-FVIII recall immune responses. Taken together, our results suggest an important adjuvant role for the complement cascade in the initiation of the immune response to therapeutic FVIII.